Statement of Principles concerning coeliac disease (Reasonable Hypothesis) (No. 29 of 2020)

The instrument operates around a small set of legal and medical concepts defined in the text and in the Schedule. Key statutory concepts are "reasonable hypothesis", "coeliac disease", "death from coeliac disease", "relevant service", and "terminal event" (see ss3, 7, Schedule 1). The Repatriation Medical Authority records that its view is grounded in "sound medical‑scientific evidence" that coeliac disease and its deaths can be related to relevant service (s8). The instrument therefore translates that view into operational factors that, if proved, satisfy the minimum evidentiary threshold for a reasonable hypothesis under the VEA framework.

Coeliac disease is defined clinically rather than solely by diagnostic coding. Subsection 7(2)(a) gives the defining pathological features: immune‑mediated mucosal inflammation of the small intestine, villous atrophy and crypt hyperplasia, triggered by hypersensitivity to ingested gluten. Subsection 7(2)(b) excludes three named conditions. A specific note records common serological associations, namely antibodies to tissue transglutaminase (tTG‑IgA) and to endomysium (EMA‑IgA). The instrument also clarifies that although the ICD‑10‑AM code K90.0 ordinarily corresponds to this condition, for the purposes of the Statement the statutory definition governs (s7(3)-(4)).

Causation is operationalised through a list of factual factors in s9 that must exist as a minimum to raise the reasonable hypothesis. These are phrased as temporal and treatment‑related facts tied to a proximate period before "clinical worsening" of coeliac disease: two specific antiviral drugs within six months (interferon alpha and ribavirin), chronic acid suppression or chronic non‑selective NSAID use for at least six months on more days than not, or the presence of inability to maintain a gluten‑free diet or inability to obtain appropriate clinical management (s9(1)-(6)). The instrument gives examples of medicines in notes to s9(3), s9(4) and s9(5).

Relationship to service is a two step test. First, the factor(s) in s9 must be related to the person's relevant service, as defined in Schedule 1 (see s10(1) and the Schedule). The Schedule defines relevant service to include various VEA categories and MRCA categories, specifically operational, peacekeeping, hazardous and British nuclear test defence under the VEA, and warlike and non‑warlike service under the MRCA. Second, s10(2) limits the s9 factors to situations where coeliac disease was suffered or contracted before or during, but did not arise out of, relevant service. Thus these factors pertain to material contribution or aggravation of a pre‑existing or contemporaneous condition, not to primary causation arising out of service.

Death is treated as included where a terminal event or condition was contributed to by the person’s coeliac disease (s7(5)). The Schedule defines "terminal event" by reference to proximate or ultimate cause of death and lists examples such as pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function.

Finally, the instrument creates a mechanism for overlap with other Statements: where a s9 factor refers to an injury or disease already the subject of another Statement of Principles under subsection 196B(2), that other Statement's factors apply as in force from time to time (s11). That establishes a cross‑reference mechanism to resolve interplay with other disease Statements.

Primary parties affected are veterans and serving members (and their dependants making claims on their behalf) who assert that coeliac disease or death from coeliac disease is related to relevant service, together with the Repatriation Medical Authority and the decision makers who apply the VEA and the Military Rehabilitation and Compensation Act 2004 (MRCA) in claim determinations (see s3, s5). The Schedule's definition of "relevant service" identifies the categories of service that bring a person within the instrument: operational, peacekeeping, hazardous and British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA. Therefore members who have performed those types of service, and who subsequently have coeliac disease, are within the instrument's reach if they make a claim under section 120A of the VEA or section 338 of the MRCA (s5, Schedule 1).

Medical practitioners and hospitals that provide clinical management, diagnostic testing and prescriptions are indirectly affected in evidentiary terms. The factors that can raise the reasonable hypothesis are frequently treatment related: history of treatment with interferon alpha or ribavirin (s9(1)-(2)), or prolonged use of proton pump inhibitors, histamine‑2 receptor antagonists, or non‑selective NSAIDs (s9(3)-(4)). The Notes to s9 list common drug examples such as esomeprazole, omeprazole and ranitidine for proton pump inhibitors and histamine‑2 antagonists (s9 Notes), and aspirin, diclofenac, ibuprofen and naproxen for non‑selective NSAIDs (s9 Note). Thus prescribing, pharmacy records and clinical management records become important evidentiary sources for claimants.

Administrative bodies responsible for claims assessment and entitlement payments under the VEA and MRCA are affected because the Statement sets the medical framework they must apply when considering whether a reasonable hypothesis exists. The instrument applies to claims to which specified sections apply (s5), and decision makers will need to check whether at least one of the s9 factors is present and related to the relevant service (s9, s10).

Dependants and estate representatives are also affected where death from coeliac disease is alleged. Section 7(5) includes death from a terminal event or condition to which coeliac disease contributed, and the Schedule defines "terminal event" by concrete examples. That means administratively that claims involving death require evidence both of the terminal event and of a contribution from coeliac disease.

Finally, other victims of the specific excluded conditions,non‑coeliac gluten sensitivity, non‑coeliac wheat protein sensitivity and wheat allergy,are affected in the sense that the instrument expressly excludes them from the statutory meaning of "coeliac disease" (s7(2)(b)). Claims premised solely on those conditions will not fall within this Statement.

This instrument is not a statute that imposes broad regulatory obligations beyond the VEA and MRCA frameworks, but it creates operational duties for decision makers and establishes the minimum evidentiary conditions that claimants must meet to raise a reasonable hypothesis linking coeliac disease or death from coeliac disease to relevant service.

Duty for decision makers: Persons deciding claims under the VEA or MRCA must apply this Statement when the claim falls within the instrument's application (s5). That means, as a starting point, they must determine whether the claimant's condition fits the statutory definition of coeliac disease in s7(2) rather than relying solely on diagnostic coding (s7(3)-(4)). They must then check whether at least one of the factors listed in s9 exists and is related to the person's relevant service as defined in the Schedule (s9, s10(1)). Where a factor in s9 refers to an injury or disease covered by another Statement of Principles, the decision maker must apply the other Statement’s factors according to its terms (s11).

Duty to consider temporal and causal relationship: Section 10 requires that s9 factors be related to relevant service and clarifies that ss9(1)-(6) are confined to material contribution to, or aggravation of, coeliac disease where the disease was suffered or contracted before or during, but did not arise out of, the person's relevant service (s10(2)). Decision makers therefore have a duty to establish both temporal sequence and service‑related causation within the statutory limits.

Claimant obligations and rights: A claimant seeking to rely on this Statement must establish at least one of the s9 factors and its relationship to relevant service (s9, s10). Practically, that means providing medical records, prescription records, treatment histories and other evidence that show the timing and nature of treatment, dietary maintenance, or access to clinical management. Where the s9 factor refers to another Statement, the claimant must also satisfy the requirements in that other Statement as in force (s11).

Rights in respect of death claims: The Statement treats death from coeliac disease as included where the coeliac disease contributed to a terminal event or condition (s7(5)). The Schedule lists examples of terminal events. This gives dependants or estate representatives a legal basis to assert that death-related entitlements should be considered under the VEA or MRCA claims processes where coeliac disease contributed to death.

Administrative rights and continuity: The instrument repeals the prior 2011 Statement (s4) and replaces it from the commencement date (s2), so claimants and decision makers have the right to the current operative text from 25 May 2020. Where other Statements are implicated by s9 factors, those Statements apply "as in force from time to time" (s11), so decision makers must take account of subsequent amendments to related Statements when they are relevant.

No expansion of criminal or civil sanctions: The instrument does not create new criminal offences or specify civil penalties. It is an evidentiary and definitional instrument to be used within the claim assessment framework under the VEA and MRCA (see ss3, 5).

The Statement of Principles itself contains no express penalties, fines or administrative sanctions. The instrument is made under subsection 196B(2) of the VEA and functions as an evidentiary and diagnostic framework to be applied by decision makers dealing with claims under specified provisions of the VEA and MRCA (s3 and s5). It does not purport to create offences or disciplinary mechanisms. Therefore enforcement in the conventional regulatory sense is not provided for in the instrument.

Enforcement in practice is administrative and indirect. Decision makers assessing claims under section 120A of the VEA or section 338 of the MRCA must apply this Statement when those provisions are engaged (s5). The effect of establishing a reasonable hypothesis under this Statement can be to trigger entitlements or further procedural steps within the VEA/MRCA claims process. Conversely, failure to satisfy the minimum factors in s9, or failure to show a service relationship under s10, means the claimant will not have raised the required reasonable hypothesis under this instrument. The Statement therefore functions as a gatekeeping tool in the administrative determination process rather than as an enforcement instrument that imposes penalties for non‑compliance.

Remedies and review mechanisms are not specified in the instrument. The instrument does not set out appeal channels, reconsideration procedures, or judicial review rights. Those procedural mechanisms, if available, arise from the VEA and MRCA frameworks and their implementing administrative law, not from this Statement. The instrument does not refer to any monitoring, auditing or compliance regime specific to this Statement.

Where a factor in s9 refers to a condition covered by another Statement of Principles, s11 requires application of that other Statement's factors as in force from time to time. That cross‑reference means that any obligations or consequences that flow from application of the other Statement will be enforced through the same administrative claim pathways. In short, the instrument itself imposes no direct penalties; its enforcement effect is to shape entitlement outcomes within the VEA and MRCA administrative processes by defining what facts will raise a reasonable hypothesis of service connection (ss9, 10).

The instrument is expressly made under the VEA,subsection 196B(2) provides the statutory power invoked (s3). It applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s5). The Schedule defines "relevant service" by reference to categories in the VEA and MRCA, including operational, peacekeeping, hazardous and British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA (Schedule 1). Therefore the Statement interacts operationally with both Acts by providing a medical causation rubric that decision makers under those Acts must apply.

The instrument expressly repeals the earlier Statement of Principles concerning coeliac disease No. 1 of 2011 (s4). That means the 2020 Statement supersedes the prior Statement for the purposes of claims under the VEA and MRCA. The repeal ensures legal continuity by replacing the earlier Statement with the current factors, definitions and cross‑references.

The Statement cross‑refers to other Statements of Principles. Section 11 provides that where a factor in s9 refers to an injury or disease covered by another Statement of Principles made under subsection 196B(2) of the VEA, then the factors in that other Statement apply in accordance with its terms as in force from time to time (s11). That gives a clear mechanism for resolving overlap between Statements. Decision makers therefore must consider not only this Statement but also the content of any other Statements implicated by a particular factor, and apply those Statements as amended.

The instrument also interacts with clinical classification systems by reference to ICD‑10‑AM. Although s7(3) states coeliac disease attracts ICD‑10‑AM code K90.0, the operator meaning for the Statement is the statutory clinical description in s7(2). Section 7(4) specifies that the reference to an ICD‑10‑AM code is to the particular edition identified, establishing the point of reference for coding when it matters in documentation.

Finally, while the Statement itself does not set out appeals or judicial review pathways, it operates within the administrative law environment that applies to decision making under the VEA and MRCA. Any overlaps or conflicts between this Statement and particular statutory provisions or other Statements will be resolved in the context of those Acts and the applicable administrative law, but the Statement does not attempt to displace those procedures. It functions as an instrument to be used by decision makers under the VEA and MRCA to assess causation and entitlement questions.

The instrument contains limited internal amendment history information. It is dated 24 April 2020 and commences on 25 May 2020 (ss1-2). Section 4 records the repeal of the earlier Statement of Principles concerning coeliac disease No. 1 of 2011 (Federal Register of Legislation No. F2010L03248), thereby replacing that instrument with the 2020 Statement (s4). No other prior amendments or versions are recorded within this instrument.

Section 11 anticipates future changes to related Statements by requiring that, where a s9 factor refers to an injury or disease covered by another Statement made under subsection 196B(2) of the VEA, the factors in that other Statement apply "as in force from time to time" (s11). That language explicitly contemplates that related Statements may be updated and that decision makers must apply their current terms. The effect is that this Statement is designed to operate alongside an evolving set of Statements of Principles, and it expressly defers to the operative text of any other relevant Statements at the time of claim assessment.

The instrument does not itself provide a schedule for future amendments, nor does it provide transitional provisions beyond the repeal of the 2011 Statement. There is no provision in the text for retrospective alteration of determinations already made; any such effect would arise from the general rules that govern application of Statements to claims under the VEA and MRCA, not from this Statement.

Because the Statement is made under subsection 196B(2) of the VEA, any further amendments to this instrument would presumably be effected by the Repatriation Medical Authority exercising that statutory power and publishing a revised Statement. Those procedural mechanics are not spelt out in this document. The instrument does not contain footnotes or annexes indicating subsequent amendments since commencement. For the purposes of claim assessment from the commencement date, this Statement takes effect as the operative instrument replacing the 2011 Statement (ss2, 4).

The instrument itself contains no recorded litigation history. It makes no reference to any court decisions, administrative review outcomes, or disputes. The only judicial or case references in the text are absent. The document is a Statement of Principles produced by the Repatriation Medical Authority under the authority of subsection 196B(2) of the VEA and is not framed as an adjudication or judicial ruling.

Because the Statement is designed to be an evidentiary tool for decision makers under the VEA and MRCA, disputes about its application could arise before the statutory review mechanisms or in judicial review proceedings. However, the instrument does not record any examples of litigation where its predecessor was challenged nor does it identify any settled legal interpretations of its terms. It also does not include interpretative rulings or policy guidance beyond the textual definitions and listed factors.

In the absence of litigation references in the instrument, interested parties must rely on the text of the Statement and its cross‑references to the VEA and MRCA when forming a view about how disputes might proceed. Any litigation history relevant to the 2011 Statement or to the assessment of coeliac disease in veterans' compensation contexts is not contained in this instrument and therefore cannot be summarised or cited here. The statutory text confined to the Statement remains the authoritative source for decision makers applying it to claims from the commencement date (s2).

There are several practical and interpretative pitfalls in applying this Statement worth attention because they affect whether a reasonable hypothesis is raised for an entitlement decision.

1. The statutory meaning of "coeliac disease" is the clinical definition in s7(2), not merely an ICD code. Although s7(3) notes coeliac disease attracts ICD‑10‑AM code K90.0, the instrument insists the operative meaning is s7(2). Claimants relying only on a coding entry without demonstrating the clinical features in s7(2) risk falling short.

2. The instrument expressly excludes non‑coeliac gluten sensitivity, non‑coeliac wheat protein sensitivity and wheat allergy (s7(2)(b)). Claims that are actually about those excluded conditions will not be captured by this Statement even if they involve gluten‑related symptoms.

3. The factors in s9 are the minimum necessary to raise a reasonable hypothesis. At least one of the listed factors must exist (s9). A claimant who cannot establish any of the specified factors will not have the minimum basis under this Statement.

4. Temporal and service relationship constraints matter. Section 10(1) requires that the s9 factor(s) be related to the relevant service. Moreover, s10(2) restricts ss9(1)-(6) to material contribution to, or aggravation of, coeliac disease where the disease was suffered or contracted before or during, but did not arise out of, the person's relevant service. That means the listed factors are intended to address aggravation or material contribution to pre‑existing or contemporaneous disease, not primary causation that arises out of service. A claimant whose coeliac disease first arose out of service will not satisfy the s10(2) scenario for application of the s9 factors.

5. "Clinical worsening" is a key temporal pivot for several factors but is not defined in the instrument. The antiviral and six‑month windows in ss9(1)-(2) and the "on more days than not, for at least the six months before the clinical worsening" language in ss9(3)-(4) all depend on identifying the date of clinical worsening. Decision makers and claimants must therefore rely on contemporaneous clinical records to establish that moment; the instrument provides no statutory definition.

6. Treatment‑based factors are specific in type and timing. Interferon alpha and ribavirin require exposure within six months before clinical worsening (ss9(1)-(2)). Acid suppression and non‑selective NSAID use require chronic use "on more days than not, for at least the six months" before clinical worsening (ss9(3)-(4)). Small differences in prescription duration, adherence, or records can determine whether the factor is established.

7. The instrument gives examples of drug names in Notes to s9 but does not limit the list. The notes provide representative examples such as esomeprazole and omeprazole for PPIs and aspirin and ibuprofen for non‑selective NSAIDs. Decision makers will need to assess whether a particular medicine falls within the described class, but the instrument leaves room for clinical interpretation.

8. The inability to maintain a gluten‑free diet and the inability to obtain appropriate clinical management are non‑treatment factors (ss9(5)-(6)). These are less amenable to clean documentary proof than prescription histories. Claimants may need to provide evidence of factors such as supply interruptions, deployment conditions, or medical access constraints to establish these factors.

9. Where an s9 factor refers to an injury or disease already covered by another Statement, that other Statement's factors apply (s11). This creates complexity where multiple Statements and medical conditions intersect. Decision makers must identify and apply the terms of the other Statement as in force, which may have different timing, definitions or evidentiary requirements.

10. Death claims require proof that coeliac disease contributed to a terminal event or condition (s7(5) and Schedule definition of "terminal event"). The Schedule lists examples such as pneumonia and respiratory failure. A claimant alleging death relatedness must therefore show both the terminal event and a contribution from coeliac disease rather than relying on a mere temporal association.

11. Administrative omission of penalties or procedural guidance is a gap. The Statement provides the medical and causal scaffolding but does not spell out procedural, evidentiary thresholds beyond the listed factors, nor does it provide examples of the standard of proof for aggravation or material contribution. That leaves room for interpretative disputes during claim assessment.

For claimants and their advisers: compliance means presenting the evidence necessary to establish that at least one of the factors in s9 existed and that the factor was related to the person's relevant service as defined in the Schedule, and ensuring the condition being claimed falls within the instrument's statutory definition of coeliac disease (ss7, 9, 10, Schedule 1).

Practical evidentiary checklist grounded in the text:

• Confirm the condition is coeliac disease as defined in s7(2). Provide clinical notes showing immune‑mediated mucosal inflammation of the small intestine, villous atrophy and crypt hyperplasia, and evidence of hypersensitivity to ingested gluten. Include serology where available. Note 1 to s7(2) mentions association with tTG‑IgA and EMA‑IgA. These serological results are relevant to establishing the clinical picture referred to in s7(2) and should be provided when available.

• Demonstrate timing of disease onset and whether the disease was suffered or contracted before or during relevant service. Section 10(2) makes this temporal relationship decisive for application of the s9 factors. Provide medical records from before, during and after service that set out dates of diagnosis, symptom onset and any documented "clinical worsening".

• Establish at least one s9 factor with contemporaneous evidence:

  • For interferon alpha or ribavirin, supply prescription records, treatment summaries or hospital charts showing therapy within the six months before the date of clinical worsening (ss9(1)-(2)). Document exact dates of start and finish, and the date of clinical worsening.
  • For proton pump inhibitors or histamine‑2 receptor antagonists, provide prescribing and dispensing records evidencing use "on more days than not, for at least the six months before the clinical worsening" (s9(3)). List drug names and dosages; notes to s9 give examples of agents.
  • For non‑selective NSAID use, produce records or reliable statements showing chronic use on more days than not for at least six months before clinical worsening (s9(4)). The note lists common NSAIDs as examples.
  • For inability to maintain a gluten‑free diet, provide deployment records, availability statements, dietary logs, or medical practitioner letters explaining the circumstances preventing maintenance of the diet at the time of clinical worsening (s9(5)).
  • For inability to obtain appropriate clinical management, supply documentation of attempted appointments, referral records, service‑related restrictions on access to specialists, or clinician statements that care was inadequate (s9(6)).

• Link the established factor to relevant service per s10(1) and the Schedule. The Schedule defines relevant service categories. Provide service records, deployment orders, and any medical incidents while serving that connect the factor to the relevant service circumstances.

• If an s9 factor touches on a condition covered by another Statement, identify that other Statement and ensure compliance with its factors as they are "in force from time to time" (s11). This can require reviewing the current text of the other Statement and providing additional evidence required there.

• For death claims, compile cause‑of‑death documentation and medical evidence showing that coeliac disease contributed to the terminal event or condition (s7(5) and Schedule definition of terminal event). Provide pathology, clinical summaries, coronial or death certificates showing the causal chain.

For decision makers and administrators: apply the instrument as the operative Statement from 25 May 2020 (s2). Use the s7(2) clinical definition rather than ICD coding alone (s7(3)-(4)). Require claimants to produce the specific types of evidence that correspond to the s9 factors and assess the temporal relationship required by s10. Where other Statements are implicated, consult and apply those Statements as in force (s11). Recognise that the instrument does not provide definitions for "clinical worsening" or standards of proof; therefore administrative practice should state the evidentiary approach it will take to determine clinical worsening and material contribution/aggravation in a transparent way.

Record keeping and documentary attention: because the s9 factors are tightly time‑bounded and therapy specific, detailed prescription and medical records are decisive. Where claimants lack contemporaneous records, written, corroborated statements explaining gaps and the basis for dates will be necessary although the instrument does not prescribe evidentiary rules for their admissibility.

Finally, remember the exclusions in s7(2)(b). If the claimant's presentation is better characterised as non‑coeliac gluten sensitivity, a wheat protein sensitivity or wheat allergy, those conditions fall outside this Statement and alternative claim strategies or diagnostic clarification will be necessary.